Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the children's cancer group
Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the children's cancer group
复制标题
DOI：
10.1007/bf00051700
复制
发表时间：
1996-11-01
影响因子：
2.3
通讯作者：
Robison, LL
中科院分区：
文献类型：
--
作者：
Ross, JA;Potter, JD;Robison, LL
近80%的婴儿白血病在11 q23处存在涉及MLL基因的异常，此外，由于已知抑制DNA拓扑异构酶II的化疗剂而发生的继发性急性髓性白血病（AML）通常表现出相同的MLL异常，据推测，新生婴儿白血病可能是由于母亲暴露于抑制DNA拓扑异构酶II的饮食和药物中，在过去的10年里，美国和加拿大的儿童癌症研究小组（CCG）用类似的方法进行了三项儿童白血病的流行病学研究，（< 12.5个月）（303例婴儿病例和468例匹配对照）在三项研究中，在美国的84个病例和97个匹配的对照中可获得关于母亲在怀孕期间暴露于潜在的DNA拓扑异构酶II抑制剂的随访问卷数据，对于母亲饮食，创建了一个复合变量，该变量由10种事先鉴定为含有DNA拓扑异构酶II抑制剂的食物组成。对于整个组或急性淋巴细胞性白血病（ALL）层，母体消耗量的增加没有显著趋势。然而，在AML层中，有统计学意义的正相关（P趋势= 0.04）随着含DNA拓扑异构酶II抑制剂食物消费量的增加（比值比[OR] = 9.8，95%置信区间[CI] = 1.1-84.8; OR = 10.2，CI = 1.1-96.4;分别用于中等和高消耗），探索其他潜在的拓扑异构酶II抑制剂;本初步研究的结果，结合分子数据，应用于儿童白血病（特别是婴儿）的进一步研究，以证明纳入详细的饮食史是合理的。
Nearly 80 percent of infant leukemias present with an abnormality involving the MLL gene at 11q23, Moreover, secondary acute myeloid leukemias (AML) that occur as the result of chemotherapy agents, which are known to inhibit DNA topoisomerase II, often manifest the same MLL abnormalities, It has been hypothesized that de novo infant leukemias may occur as a result of maternal exposure to agents in diet and medications that inhibit DNA topoisomerase II, Three epidemiologic studies of childhood leukemia with similar methodologies were conducted in the United States and Canada over the past 10 years by the Children's Cancer Group (CCG), Of the total 771 mothers of infants diagnosed at one year of age or less (< 12.5 months) who originally were interviewed (303 infant cases and 468 matched controls) across the three studies, follow-up questionnaire data on maternal exposure to potential DNA topoisomerase II inhibitors during pregnancy were available on 84 cases and 97 matched controls in the US, For maternal diet, a composite variable was created that consisted of 10 foods identified a priori as containing DNA topoisomerase II inhibitors, There were no significant trends with increasing maternal consumption for either the overall group, or the acute lymphoblastic leukemia (ALL) stratum, However, within the AML stratum, there was a statistically significant positive association (P trend = 0.04) with increasing consumption of DNA topoisomerase II-inhibitor containing foods (odds ratio [OR] = 9.8, 95 percent confidence interval [CI] = 1.1-84.8; OR = 10.2, CI = 1.1-96.4; for medium and high consumption, respectively), Other potential topoisomerase II inhibitors were explored; no significant findings were found, Results of this preliminary study, in combination with molecular data, should be used in future investigations of childhood leukemia (particularly, infant) to justify the incorporation of a detailed dietary history.